Therapy Areas: Central Nervous System
Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis
31 October 2017 - - US-based biopharmaceutical company Longevity Biotech, Inc. has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society's commercial research funding programme, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent, the company said.

This programme aims to determine the ability of LBT-3627 to protect and repair damaged neurons while also restoring balance to the immune system.

The grant establishes another neurodegenerative immune disorder program for LBT-3627, which is also in development for Parkinson's disease among other neurological disorders.

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body.

Symptoms vary from person to person and range from numbness and tingling, to walking difficulties, fatigue, dizziness, pain, depression, blindness and paralysis.

The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS.

Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3m worldwide.

Various strategies have been employed to treat MS, including anti-inflammatory agents and immunomodulators; however, there is still no cure. Agents that directly protect neurons and promote remyelination are critically needed.

Longevity Biotech, Inc. is a preclinical-stage biopharmaceutical company pursuing numerous innovative programs based on the patented Hybridtide platform technology.

LBT's candidates display unique attributes that are expected to provide either first-in-class or best-in-class product profiles in their respective indication.

The Hybridtide technology can be applied to most peptides and is available for partnership and/or co-development efforts as appropriate.

The Society in 2016 devoted more than USD 100m to connect approximately 1m people affected by MS to the connections, information and resources.

It also invested USD 42m to support more than 380 new and ongoing research projects around the world.
Login
Username:

Password: